Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA

DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announced it has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news